Current understanding of the molecular basis of CRC and identification of specific cell surface receptors for peptide ligands will support the nanoparticle-based targeting of combination chemotherapeutic agents and/or monoclonal antibodies to the cells in ways that will minimize the off-target binding, enable high target specificity, and preserve normal cells. The gene discussed is CD177; the disease is colorectal carcinoma.